Javid Moslehi, MD
Professor
Medicine
School of Medicine

Cardio-Oncology, Cardio-Immunology

RESEARCH INTERESTS: I am a cardiologist and myocyte biologist. My clinical focus is cardio-oncology and cardio-immunology. My clinical interests overlap with my laboratory focus, where we are investigating the mechanistic underpinnings of cardiovascular sequelae of novel targeted and immune-based cancer therapies.

Since 2016, a major focus of my clinical and research program has been the interaction between the cardiovascular and immune systems. Our group initially described a novel clinical syndrome of fulminant myocarditis that arises from (ICI) immune checkpoint inhibitors (Johnson et al, NEJM, 2016). We further defined the clinical characteristics of ICI-associated myocarditis (Moslehi et al, Lancet, 2018) and showed that cardiovascular sequelae of ICI include pericarditis, vasculitis and arrhythmias (Salem et al, Lancet Oncology, 2018). My laboratory has generated mouse models that recapitulate these novel immune-based clinical syndromes which have provided insights into new diagnostic and treatment strategies for these complications (Bonaca et al, Circulation, 2019; Salem et al, NEJM, 2019; Wei et al, Cancer Discovery, 2021). My interest in this space has recently expanded to other inflammatory cardiomyopathies, including giant cell myocarditis, acute cellular rejection (ACR) following cardiac transplantation, and other forms of myocarditis. Our group is further investigating the how the immune system can be harnessed to treat heart disease.

• Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response.
  Circulation research 2024 Liang FG, Moslehi J, Kitsis RN
• Genetic Interleukin-6 Receptor Variant Is Not Associated With Rejection and Mortality After Heart Transplantation.
  Journal of cardiac failure 2024 Amancherla K, Schlendorf KH, Vlasschaert C, Lowery BD, Wells QS, See SB, Zorn E, Colombo PC, Reilly MP, Lindenfeld J, Uriel N, Shah RV, Freedman JE, Moslehi J, Bick AG, Clerkin K
• Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
  Nature medicine 2023 Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, …
• Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
  Nature medicine 2023 Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, …
• Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
  The oncologist 2023 Bonaca MP, Moslehi JJ, Ledermann JA, Michelon E, Wei C, Moran M, Monk BJ, Pujade-Lauraine E
• Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
  Circulation 2023 Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, Jimenez J, He R, Parks A, Amrute J, Villanueva A, Liu Y, Lin CY, Mack M, Amancherla K, Moslehi J, Lavine KJ
• CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis.
  Circulation research 2023 Régnier P, Le Joncour A, Maciejewski-Duval A, Darrasse-Jèze G, Dolladille C, Meijers WC, Bastarache L, Fouret P, Bruneval P, Arbaretaz F, Sayetta C, Márquez A, Rosenzwajg M, Klatzmann D, Cacoub P, …
• Immune Checkpoint Inhibitors' Effects on Calcified Aortic Plaques in Melanoma Survivors: A Retrospective Cohort Study.
  JACC. CardioOncology 2023 Turker I, Nair S, Terry JG, Huang S, Carr JJ, Moslehi JJ, Gupta DK, Alexander MR, Johnson DB
• Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
  Circulation 2023 Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, Stein F, Bretagne M, Ederhy S, Fenioux C, Hamwy O, Funck-Brentano E, Romano E, Pieroni L, Münster JP, Allenbach Y, Anquetil C, …
• Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study.
  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2023 Amancherla K, Schlendorf KH, Vlasschaert C, Lowery BD, Wells QS, See SB, Zorn E, Colombo PC, Reilly MP, Lindenfeld J, Uriel N, Freedman JE, Shah RV, Moslehi J, Bick AG, Clerkin K
• Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
  Cancer discovery 2023 Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, Boussouar S, Nguyen LS, Procureur A, Stein F, Fenioux C, Devos P, Gougis P, Dres M, Demoule A, Psimaras D, Lenglet T, Maisonobe T,…
• A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2023 Chen YC, Jaffer M, Zhou L, Moslehi J, Forsyth PA, Fecher LA
• Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
  bioRxiv : the preprint server for biology 2023 Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, Jimenez J, Parks A, Amrute J, Villanueva A, Liu Y, Lin CY, Mack M, Amancherla K, Moslehi J, Lavine KJ
• Circulating immune checkpoints predict heart failure outcomes.
  ESC heart failure 2023 Screever EM, Yousif LIE, Moslehi JJ, Salem JE, Voors AA, Silljé HHW, de Boer RA, Meijers WC
• The next big questions in cancer research.
  Cell 2023 Loi S, Settleman J, Joyce JA, Pramesh CS, Bernards R, Fan J, Merchant JL, Moslehi J, Sellers WR
• Diagnosis and Treatment of Acute Myocarditis: A Review.
  JAMA 2023 Ammirati E, Moslehi JJ
• Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
  Journal for immunotherapy of cancer 2023 Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, Krug LM, Moslehi J, Pietanza MC, Riemer J, Robert C, Sharon E, Suarez-Almazor ME, Suresh K, Turner M, Weber J, Cappelli LC
• Addressing cardiovascular complications of BTK inhibitors.
  Clinical advances in hematology & oncology : H&O 2023 Moslehi J
• Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review.
  Journal of gastrointestinal cancer 2023 Chan H, Savoie MB, Munir A, Moslehi J, Anwar M, Laffan A, Rowen T, Salmon R, Varma M, Van Loon K
• Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions.
  JACC. CardioOncology 2022 Moslehi J, Salem JE
• Single-Nuclear RNA Sequencing of Endomyocardial Biopsies Identifies Persistence of Donor-Recipient Chimerism With Distinct Signatures in Severe Cardiac Allograft Vasculopathy.
  Circulation. Heart failure 2022 Amancherla K, Qin J, Hulke ML, Pfeiffer RD, Agrawal V, Sheng Q, Xu Y, Schlendorf KH, Lindenfeld J, Shah RV, Freedman JE, Tucker NR, Moslehi J
• T cells specific for α-myosin drive immunotherapy-related myocarditis.
  Nature 2022 Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, …
• Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities.
  Science advances 2022 Spetz JKE, Florido MHC, Fraser CS, Qin X, Choiniere J, Yu SJ, Singh R, Friesen M, Rubin LL, Salem JE, Moslehi JJ, Sarosiek KA
• Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.
  Science translational medicine 2022 Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, …
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
  European heart journal 2022 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog…
• Reply to S. Rossi et al and P. Palassin et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Naqash AR, Johnson DB, Moslehi JJ, Sharon E
• A Pilot Study of Associations Between the Occurrence of Palpitations and Cytokine Gene Variations in Women Prior to Breast Cancer Surgery.
  Biological research for nursing 2022 Sheng Y, Carpenter JS, Smith BJ, Paul SM, Melisko M, Moslehi J, Levine JD, Conley YP, Kober KM, Miaskowski C
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
  European heart journal. Cardiovascular Imaging 2022 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog…
• Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma.
  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2022 Tai W, Doolittle GC, Shah Z, Atkinson JB, Russell E, Genton RE, Moslehi JJ, Porter CB
• Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.
  European journal of cancer (Oxford, England : 1990) 2022 Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Itzhaki …
• Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism.
  The Journal of clinical investigation 2022 Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, Basta P, Krolczyk J, Sulicka-Grodzicka J, Jozefczuk E, Dziewulska A,…
• Reply to S. Tan et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Rini BI, Moslehi JJ, Hariharan S
• Expanding the Therapeutic World of Tryptophan Metabolism.
  Circulation 2022 Wyant GA, Moslehi J
• AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease.
  Journal of the American Geriatrics Society 2022 Mohile S, Blaum CS, Abadir PM, Dale W, Forman DE, Fung C, Holmes HM, Moslehi J, Mustian KM, Rich MW, Whitson HE
• Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Naqash AR, Moey MYY, Cherie Tan XW, Laharwal M, Hill V, Moka N, Finnigan S, Murray J, Johnson DB, Moslehi JJ, Sharon E
• Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
  Haematologica 2022 Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR
• Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis.
  Archives of cardiovascular diseases 2022 Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehmann LH, Ederhy S, …
• Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.
  Nature reviews. Cardiology 2022 Karlstaedt A, Moslehi J, de Boer RA
• Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
  Journal for immunotherapy of cancer 2022 Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J, Rosenzwajg M, Salem JE
• Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.
  Frontiers in medicine 2022 Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, Pineton de Chambrun M, Cereda A, Picchi C, Trotta L, Moslehi JJ, Brucato A
• Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J
• Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
  Circulation research 2022 Wilcox NS, Rotz SJ, Mullen M, Song EJ, Ky Hamilton B, Moslehi J, Armenian SH, Wu JC, Rhee JW, Ky B
• 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis.
  Archives of cardiovascular diseases 2022 Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, Cohen AA, Moslehi J, Bretagne M, Allenbach Y, Kharroubi D, Salem JE
• Immune-checkpoint inhibitors: long-term implications of toxicity.
  Nature reviews. Clinical oncology 2022 Johnson DB, Nebhan CA, Moslehi JJ, Balko JM
• Harnessing big data to characterize immune-related adverse events.
  Nature reviews. Clinical oncology 2022 Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L
• Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database.
  Nature communications 2022 Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, Hekimian G, Ammirati E, Ben M'Barek B, Redheuil A, Gandjbakhch E, Bihan K, Lebrun-Vignes B, Ederhy S, Dolladille C, Moslehi JJ,…
• Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association.
  Circulation 2021 Zaha VG, Hayek SS, Alexander KM, Beckie TM, Hundley WG, Kondapalli L, Ky B, Leger KJ, Meijers WC, Moslehi JJ, Shah SH
• Editorial: Recent Advances in Cardiotoxicity Testing.
  Frontiers in pharmacology 2021 Mohamed TMA, Moslehi J, Satin J
• Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
  JAMA cardiology 2021 Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Müller OJ, Aras M, Asnani AH, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek SS, Ederhy S, Salem JE, …
• Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis.
  Circulation 2021 Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehman L, Ederhy S, …
• Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.
  European heart journal 2021 Salem JE, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, Funck-Brentano C, Gougis P
• 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
  Journal for immunotherapy of cancer 2021 Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M
• PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.
  Circulation. Heart failure 2021 Choudhary A, Brinkley DM, Besharati S, Meijers WC, Atkinson JB, Amancherla K, Zhu Q, Huang S, Nguyen LS, Salem JE, Ammirati E, Lindenfeld J, Anders RA, Moslehi J
• High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy.
  Clinical hematology international 2021 Hu JR, Patel A, Huang S, Su YR, Dahlman KB, Tomasek K, Zhang Y, O'Neil RT, O'Neal JF, Turker I, Johnson DB, Salem JE, Moslehi JJ, Oluwole O
• Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
  European heart journal. Cardiovascular pharmacotherapy 2021 Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C
• Survivorship, Version 1.2021.
  Journal of the National Comprehensive Cancer Network : JNCCN 2021 Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, Armenian S, Baker KS, Broderick G, Day A, Demark-Wahnefried W, Dickinson K, Friedman DL, Ganz P, Goldman M, Henry NL, Hill-Kayser C, Hudson M, …
• Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
  American journal of hematology 2021 Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, Moslehi JJ, Dechartres A, Salem JE
• RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets.
  Circulation research 2021 Amancherla K, Qin J, Wang Y, Axelrod ML, Balko JM, Schlendorf KH, Hoffman RD, Xu Y, Lindenfeld J, Moslehi J
• Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
  Circulation research 2021 Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ
• Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
  Circulation research 2021 Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ
• Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
  Circulation research 2021 Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H, American Heart Association Council on Basic Cardiovascular Sciences; Cardio-Oncology Science …
• Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
  Cancer 2021 Butler SS, Mahal BA, Moslehi JJ, Nohria A, Dee EC, Makkar R, Whitbeck A, Wangoe J, Mouw KW, Nguyen PL, Muralidhar V
• High-grade heart block associated with ibrutinib therapy.
  HeartRhythm case reports 2021 Vartanov AR, Lampson BL, Jacobsen ED, Alyea EP, Moslehi JJ, Brown JR
• Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
  European journal of cancer (Oxford, England : 1990) 2021 Nguyen LS, Ortuno S, Lebrun-Vignes B, Johnson DB, Moslehi JJ, Hertig A, Salem JE
• Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
  The Journal of clinical investigation 2021 Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN
• Standing at the Crossroads.
  Cancer cell 2021 Tang L, Moslehi J, Tang Y
• Global Longitudinal Strain in Cardio-Oncology.
  Journal of the American College of Cardiology 2021 Moslehi JJ, Witteles RM
• Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.
  JAMA oncology 2021 Ratain MJ, Moslehi JJ, Lichter AS
• Implementation of Cardio-Oncology Training for Cardiology Fellows.
  JACC. CardioOncology 2020 Tuzovic M, Brown SA, Yang EH, West BH, Bassi NS, Park S, Guha A, Ghosh AK, Ganatra S, Hayek SS, Moslehi J, Jahangir E
• Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.
  Arteriosclerosis, thrombosis, and vascular biology 2020 Wu MD, Moslehi JJ, Lindner JR
• A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
  Cancer discovery 2020 Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li …
• Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
  European journal of heart failure 2020 de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, Bauersachs J, Bertero E, Coats AJS, Celutkiene J, Chioncel O, Dodion P, Eschenhagen T, Farmakis D, Bayes-Genis A, Jäger D, …
• Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.
  Circulation. Heart failure 2020 Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tschöpe C, Cooper LT, Camici PG
• Age-Related Considerations in Cardio-Oncology.
  Journal of cardiovascular pharmacology and therapeutics 2020 Screever EM, Meijers WC, Moslehi JJ
• Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
  Circulation 2020 Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, Tedeschi J, Lebrun-Vignes B, Lundby A, Sadreyev RI, Moslehi J, Nahrendorf M, Ellinor PT, …
• Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study.
  Pharmaceuticals (Basel, Switzerland) 2020 Hilmi M, Ederhy S, Waintraub X, Funck-Brentano C, Cohen A, Vozy A, Lebrun-Vignes B, Moslehi J, Nguyen LS, Salem JE
• Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
  European journal of heart failure 2020 Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Šterba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker…
• The cancer patient and cardiology.
  European journal of heart failure 2020 Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, …
• Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
  Urologic oncology 2020 Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O
• Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
  JACC. CardioOncology 2020 Aras MA, Power JR, Moslehi JJ
• Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
  Annual review of pharmacology and toxicology 2020 Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, Funck-Brentano E, Moslehi JJ, Johnson DB, Salem JE
• Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.
  Toxicology and applied pharmacology 2020 Miller JM, Meki MH, Ou Q, George SA, Gams A, Abouleisa RRE, Tang XL, Ahern BM, Giridharan GA, El-Baz A, Hill BG, Satin J, Conklin DJ, Moslehi J, Bolli R, Ribeiro AJS, Efimov IR, Mohamed TMA
• Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.
  Journal of molecular and cellular cardiology 2020 Li C, Jiang J, Wang F, Zhou N, Veronese G, Moslehi JJ, Ammirati E, Wang DW
• Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
  Journal of the American Heart Association 2020 Chen C, Wang F, Chen P, Jiang J, Cui G, Zhou N, Moroni F, Moslehi JJ, Ammirati E, Wang DW
• Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity.
  Circulation 2020 Moslehi J, Zhang Q, Moore KJ
• Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
  Annual review of pharmacology and toxicology 2020 Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem JE, Wu SM, Moslehi JJ, Zhu H
• Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
  European journal of heart failure 2020 Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, …
• Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.
  The Lancet. Oncology 2020 Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J, Moslehi JJ
• NCCN Guidelines Insights: Survivorship, Version 2.2020.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, …
• Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.
  British journal of clinical pharmacology 2020 Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, Phillips EJ
• Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
  Journal for immunotherapy of cancer 2020 Young AC, Quach HT, Song H, Davis EJ, Moslehi JJ, Ye F, Williams GR, Johnson DB
• Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
  European journal of cancer (Oxford, England : 1990) 2020 Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB
• Tissue Is the Issue, Even During a Pandemic.
  Circulation 2020 Shah KS, Moslehi JJ, Fang JC
• Inflammation begets inflammation: cancer and acute MI.
  European heart journal 2020 Kondapalli L, Moslehi J, Bonaca MP
• Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
  Autoimmunity reviews 2020 Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano JP, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem JE
• Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis.
  The European respiratory journal 2020 Moey MYY, Gougis P, Goldschmidt V, Johnson DB, Lebrun-Vignes B, Moslehi J, Cadranel J, Salem JE
• Vascular medicine and cardio-oncology - A new, evolving clinical frontier.
  Vascular medicine (London, England) 2020 Versmissen J, Power JR, Moslehi J
• Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.
  Circulation 2020 Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, Moslehi JJ, Roden DM, Funck-Brentano C, Salem JE
• Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective.
  Journal of the American College of Cardiology 2020 Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ
• Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
  The oncologist 2020 Grouthier V, Lebrun-Vignes B, Moey M, Johnson DB, Moslehi JJ, Salem JE, Bachelot A
• Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
  European heart journal 2020 Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, …
• COVID-19 and immune checkpoint inhibitors: initial considerations.
  Journal for immunotherapy of cancer 2020 Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL
• Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.
  Cancer immunology research 2020 Shah KP, Song H, Ye F, Moslehi JJ, Balko JM, Salem JE, Johnson DB
• Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
  British journal of haematology 2020 Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G
• Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.
  Annales d'endocrinologie 2020 Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM
• Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.
  Circulation. Cardiovascular quality and outcomes 2020 Ruddy KJ, Sangaralingham LR, Van Houten H, Nowsheen S, Sandhu N, Moslehi J, Neuman H, Jemal A, Haddad TC, Blaes AH, Villarraga HR, Thompson C, Shah ND, Herrmann J
• Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes".
  Circulation 2020 Salem JE, Moslehi JJ, Funck Brentano C, Roden DM
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R,…
• Solid organ transplant rejection associated with immune-checkpoint inhibitors.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Saberianfar S, Nguyen LS, Manouchehri A, Lebrun-Vignes B, Moslehi JJ, Johnson DB, Hertig A, Salem JE
• Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
  Arteriosclerosis, thrombosis, and vascular biology 2020 Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ
• Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.
  Journal of the American Heart Association 2020 Aboumsallem JP, Moslehi J, de Boer RA
• Cardio-Immuno-Oncology.
  Circulation 2020 Zaha VG, Meijers WC, Moslehi J
• Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association.
  Circulation 2020 Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Ca
• The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.
  The Journal of clinical investigation 2020 Moslehi J, Rathmell WK
• Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care.
  Arteriosclerosis, thrombosis, and vascular biology 2019 Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J
• Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].
  American heart journal 2019 Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF
• Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.
  Current cardiology reports 2019 Ala CK, Klein AL, Moslehi JJ
• Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
  Urologic oncology 2019 Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan…
• Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
  JAMA 2019 Meijers WC, Moslehi JJ
• Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
  Seminars in oncology 2019 Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G
• Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
  Archives of cardiovascular diseases 2019 Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE
• Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
  European journal of cancer (Oxford, England : 1990) 2019 Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE
• Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.
  Heart failure reviews 2019 Cadeddu Dessalvi C, Pepe A, Penna C, Gimelli A, Madonna R, Mele D, Monte I, Novo G, Nugara C, Zito C, Moslehi JJ, de Boer RA, Lyon AR, Tocchetti CG, Mercuro G
• Cancer cachexia: getting to the heart of the matter.
  European heart journal 2019 Groarke JD, Cheng S, Jones LW, Moslehi J
• Cardiovascular Toxicities Associated With Ibrutinib.
  Journal of the American College of Cardiology 2019 Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ
• Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.
  JACC. CardioOncology 2019 Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, Chandra A, Haykowsky M, Ky B, Moslehi J, Nohria A, Butler J, Pandey A
• Comparative Transcriptomics of Ex Vivo, Patient-Derived Endothelial Cells Reveals Novel Pathways Associated With Type 2 Diabetes Mellitus.
  JACC. Basic to translational science 2019 Beckman JA, Doherty SP, Feldman ZB, Banks ES, Moslehi J, Jaffe IZ, Hamburg NM, Sheng Q, Brown JD
• Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.
  Circulation 2019 Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM
• Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.
  Journal of the American College of Cardiology 2019 Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL
• Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis.
  Journal of the American College of Cardiology 2019 Moslehi JJ, Brinkley DM, Meijers WC
• A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.
  Nature medicine 2019 Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV…
• Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
  Circulation 2019 Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera …
• NCCN Guidelines Insights: Survivorship, Version 2.2019.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Sanft T, Denlinger CS, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Mooney K, Moore …
• Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
  The New England journal of medicine 2019 Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M
• Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, …
• Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
  European heart journal 2019 Stack JP, Moslehi J, Sayed N, Wu JC
• Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
  American journal of physiology. Heart and circulatory physiology 2019 Beyer AM, Bonini MG, Moslehi J
• Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis.
  International journal of molecular sciences 2019 Linton MF, Moslehi JJ, Babaev VR
• Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
  Journal for immunotherapy of cancer 2019 Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE
• Assessing cardiac safety in oncology drug development.
  American heart journal 2019 Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF
• Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need.
  Cardiovascular research 2019 Moslehi J, Fujiwara K, Guzik T
• Cardiovascular toxicities associated with immune checkpoint inhibitors.
  Cardiovascular research 2019 Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J
• Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
  European journal of cancer (Oxford, England : 1990) 2019 Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE
• Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review.
  JAMA cardiology 2019 Calvillo-Argüelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, Thavendiranathan P
• Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.
  Journal of the American College of Cardiology 2019 Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP
• Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
  Circulation 2019 Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL
• Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
  European journal of cancer (Oxford, England : 1990) 2019 Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A
• Hematologic Complications of Immune Checkpoint Inhibitors.
  The oncologist 2019 Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB
• Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
  Frontiers in oncology 2019 Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D, Harrell S, Hall R, Wyatt H, Piazza G
• Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
  Journal for immunotherapy of cancer 2019 Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, …
• The forgotten right ventricle in cardio-oncology.
  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2019 Jahangir E, Harinstein ME, Murthy VL, Moslehi J
• Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
  Blood 2019 Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR
• Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
  British journal of haematology 2018 Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, …
• Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
  JAMA oncology 2018 Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B…
• Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
  The Lancet. Oncology 2018 Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ
• Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.
  Diabetes care 2018 Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC
• Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study.
  eLife 2018 Salisbury-Ruf CT, Bertram CC, Vergeade A, Lark DS, Shi Q, Heberling ML, Fortune NL, Okoye GD, Jerome WG, Wells QS, Fessel J, Moslehi J, Chen H, Roberts LJ, Boutaud O, Gamazon ER, Zinkel SS
• Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, …
• Immune checkpoint inhibitors and cardiovascular toxicity.
  The Lancet. Oncology 2018 Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J
• Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients.
  Journal of oncology and cancer research 2018 Das S, Pineda G, Berlin J, Hemphill B, Moslehi J, Nohria A, Fisher G
• Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.
  Circulation 2018 Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y
• Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.
  Lancet (London, England) 2018 Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB
• Hypogonadism as a Reversible Cause of Torsades de Pointes in Men.
  Circulation 2018 Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, …
• Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM
• Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
  The oncologist 2018 Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ, Checkpoint Inhibitor Safety Working Group
• Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018 Blaes AH, Thavendiranathan P, Moslehi J
• In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.
  Journal of chemical information and modeling 2018 Cai C, Fang J, Guo P, Wang Q, Hong H, Moslehi J, Cheng F
• Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
  Heart (British Cardiac Society) 2018 Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE
• Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.
  Pharmacology & therapeutics 2018 Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE
• Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase.
  Proceedings of the National Academy of Sciences of the United States of America 2018 McBrayer SK, Olenchock BA, DiNatale GJ, Shi DD, Khanal J, Jennings RB, Novak JS, Oser MG, Robbins AK, Modiste R, Bonal D, Moslehi J, Bronson RT, Neuberg D, Nguyen QD, Signoretti S, Losman JA, Kaelin …
• Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.
  The Journal of pharmacology and experimental therapeutics 2018 Yang T, Meoli DF, Moslehi J, Roden DM
• Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment.
  Current treatment options in cardiovascular medicine 2018 Spetz J, Moslehi J, Sarosiek K
• Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
  Journal of the American College of Cardiology 2018 Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, …
• Comorbidities: Cardiovascular disease and breast cancer.
  Nature reviews. Cardiology 2018 Moey M, Moslehi J
• Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
  Lancet (London, England) 2018 Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB
• Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
  Hypertension (Dallas, Tex. : 1979) 2017 Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J
• Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
  Hematology. American Society of Hematology. Education Program 2017 Barber MC, Mauro MJ, Moslehi J
• The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.
  Clinical genitourinary cancer 2017 Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR
• Smoldering myocarditis following immune checkpoint blockade.
  Journal for immunotherapy of cancer 2017 Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM
• Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
  British journal of haematology 2017 Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J
• Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney …
• Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy.
  eLife 2017 Litt MJ, Okoye GD, Lark D, Cakir I, Moore C, Barber MC, Atkinson J, Fessel J, Moslehi J, Cone RD
• Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
  Haematologica 2017 Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, …
• Grounding Cardio-Oncology in Basic and Clinical Science.
  Circulation 2017 Moslehi J, Amgalan D, Kitsis RN
• Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
  JAMA oncology 2017 Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J
• Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
  Current hematologic malignancy reports 2017 Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM
• A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
  British journal of haematology 2017 Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, …
• Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors, Salt, and Macrophages: A Complicated Interaction.
  Hypertension (Dallas, Tex. : 1979) 2017 Moslehi J, Pandey AK, Bhatia N
• Cardiovascular Toxicities Associated with Cancer Immunotherapies.
  Current cardiology reports 2017 Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ
• Cardio-Oncology: Time to Get More Mechanistic.
  JACC. Basic to translational science 2017 Moslehi J, Lenihan DJ
• Ventricular arrhythmias and sudden death in patients taking ibrutinib.
  Blood 2017 Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR
• High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
  Science translational medicine 2017 Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC
• Myocarditis with Immune Checkpoint Blockade.
  The New England journal of medicine 2017 Moslehi JJ, Johnson DB, Sosman JA
• Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.
  Cancer cell 2016 Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy …
• Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, …
• Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
  The New England journal of medicine 2016 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS,…
• Cardiovascular Toxic Effects of Targeted Cancer Therapies.
  The New England journal of medicine 2016 Moslehi JJ
• 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.
  JACC. Basic to translational science 2016 Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J
• NCCN Guidelines Insights: Survivorship, Version 1.2016.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan …
• Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.
  The oncologist 2016 Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH
• EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.
  Cell 2016 Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG
• Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty.
  Journal of cardiac failure 2016 Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G,…
• Cardiovascular Complications of Novel Multiple Myeloma Treatments.
  Circulation 2016 Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J
• EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.
  Cell 2016 Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG
• Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.
  Circulation 2016 Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J
• Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
  JAMA oncology 2016 Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM
• Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
  Circulation 2015 Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ
• Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training.
  Critical reviews in oncology/hematology 2015 Scott JM, Armenian S, Giralt S, Moslehi J, Wang T, Jones LW
• Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis.
  Circulation 2015 Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J
• Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Moslehi JJ, Deininger M
• Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.
  Journal of the American College of Cardiology 2015 Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J
• QT Prolongation and Oncology Drug Development.
  Cardiac electrophysiology clinics 2015 Fradley MG, Moslehi J
• Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes.
  Journal of the American College of Cardiology 2015 Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A
• Survivorship: screening for cancer and treatment effects, version 2.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, …
• ABCDE steps to prevent heart disease in breast cancer survivors.
  Circulation 2014 Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J
• Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, …
• Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary.
  Journal of the American College of Cardiology 2014 Koelwyn GJ, Jones LW, Moslehi J
• Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
  Current treatment options in cardiovascular medicine 2014 Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J
• Survivorship: healthy lifestyles, version 2.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, …
• Survivorship: immunizations and prevention of infections, version 2.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, …
• The challenge of cross-trial comparisons using limited data.
  Haematologica 2014 Laubach JP, Faber EA, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG
• Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.
  Genes & development 2014 Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, …
• Survivorship: cognitive function, version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, …
• Cardiology patient page. Breast cancer chemotherapy and your heart.
  Circulation 2014 Unitt C, Montazeri K, Tolaney S, Moslehi J
• Survivorship: fatigue, version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, …
• Survivorship: sleep disorders, version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, …
• Survivorship: pain version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, …
• D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
  Genes & development 2014 Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe …
• Heart failure and breast cancer therapies: moving towards personalized risk assessment.
  Journal of the American Heart Association 2014 Francis SA, Cheng S, Arteaga CL, Moslehi J
• Real-time three-dimensional transoesophageal echocardiography enables preoperative pulmonary valvulopathy assessment.
  European heart journal. Cardiovascular Imaging 2013 Waller AH, Chatzizisis YS, Moslehi JJ, Chen FY, Mangion JR
• Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging.
  Cell 2013 Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA
• Cancer-drug discovery and cardiovascular surveillance.
  The New England journal of medicine 2013 Groarke JD, Cheng S, Moslehi J
• A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease.
  Journal of the American Society of Nephrology : JASN 2013 Liu D, Wang CJ, Judge DP, Halushka MK, Ni J, Habashi JP, Moslehi J, Bedja D, Gabrielson KL, Xu H, Qian F, Huso D, Dietz HC, Germino GG, Watnick T
• MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.
  Circulation research 2013 Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, Cheng HW, Raghuram S, Arany Z, Liao R, Croce K, MacRae C, Feinberg MW
• Emerging paradigms in cardiomyopathies associated with cancer therapies.
  Circulation research 2013 Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ
• Cardio-oncology: it takes two to translate.
  Science translational medicine 2013 Moslehi J, Cheng S
• Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease.
  European heart journal 2013 Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J
• The cardiovascular perils of cancer survivorship.
  The New England journal of medicine 2013 Moslehi J
• Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
  Trends in cardiovascular medicine 2013 Bair SM, Choueiri TK, Moslehi J
• Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
  The American journal of cardiology 2012 Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M
• Breast cancer therapies and cardiomyopathy.
  The Medical clinics of North America 2012 Groarke J, Tong D, Khambhati J, Cheng S, Moslehi J
• Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
  The American journal of cardiology 2012 Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY
• Management of antiangiogenic therapy-induced hypertension.
  Hypertension (Dallas, Tex. : 1979) 2012 de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD
• Treatment of erythropoietin deficiency in mice with systemically administered siRNA.
  Blood 2012 Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG
• Telomeres and mitochondria in the aging heart.
  Circulation research 2012 Moslehi J, DePinho RA, Sahin E
• You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes.
  Circulation research 2012 Moslehi J, Libby P
• Reversible cardiomyopathy associated with sunitinib and sorafenib.
  The New England journal of medicine 2011 Uraizee I, Cheng S, Moslehi J
• Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.
  Circulation 2011 Nazer B, Humphreys BD, Moslehi J
• Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK
• Telomere dysfunction induces metabolic and mitochondrial compromise.
  Nature 2011 Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, …
• Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.
  Circulation 2010 Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG
• A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo.
  Molecular and cellular biology 2009 Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG
• Paragangliomas: etiology, presentation, and management.
  Cardiology in review 2009 Joynt KE, Moslehi JJ, Baughman KL
• Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature.
  The American journal of cardiology 2008 Sung AD, Cheng S, Moslehi J, Scully EP, Prior JM, Loscalzo J
• Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure.
  Blood 2007 Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG
• cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
  Circulation research 2004 Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA
• Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
  Molecular and cellular biology 2002 Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ
• An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells.
  EMBO reports 2002 Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG
• Posterior urethral valves presented at birth despite normal prenatal ultrasound scans.
  Urology 2001 Moslehi J, Herndon CD, McKenna PH
• Nucleated conformational conversion and the replication of conformational information by a prion determinant.
  Science (New York, N.Y.) 2000 Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf MF, Lindquist SL
• Yeast prion [psi +] and its determinant, Sup35p.
  Methods in enzymology 1999 Serio TR, Cashikar AG, Moslehi JJ, Kowal AS, Lindquist SL
• Influence of antigen organization on the development of lupus autoantibodies.
  Arthritis and rheumatism 1998 Fatenejad S, Bennett M, Moslehi J, Craft J
• Perforin protects against autoimmunity in lupus-prone mice.
  Journal of immunology (Baltimore, Md. : 1950) 1998 Peng SL, Moslehi J, Robert ME, Craft J
• Roles of interferon-gamma and interleukin-4 in murine lupus.
  The Journal of clinical investigation 1997 Peng SL, Moslehi J, Craft J